Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Adlai Nortye Ltd.NASDAQ: ANL

Depreciation & Amortization · Q2 FY2024 · quarter ended Jun 2024

Depreciation & amortization declines year over year

Q2 FY2024 depreciation & amortization of $266K fell 59.3% year over year, behind the -34.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -11.5% a year.

Context

  • Depreciation & amortization amounted to 28.3% of revenue in FY2025.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -59.3% toward the trailing-twelve-month pace of -34.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2024
$266K+0.0% QoQ
Last fiscal yearDec 2025
$1.41M-24.4% YoY
LTMJun 2024
$1.1M-34.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.3%——
1 year-24.4%——
3-year CAGR-11.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.41M USD
Year-over-year change
-24.4%
4-year CAGR
-6.2%

Depreciation & Amortization vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's LTM Jun 2024 depreciation & amortization of $1.1M is the 3rd highest of the 7 companies compared; the peer median is $626K.
  • Depreciation & amortization amounts to 16.9% of revenue for ANL, versus a peer median of 2.0%.
ANL Competitors Peer median
Depreciation & Amortization for ANL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$2.79M -10.3%+0.1%9.9%
NUVBNuvation Bio Inc.LTM Jun 2026$2.15M +104.9%+106.0%1.3%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.1M —-11.5%16.9%
VSTMVerastem, Inc.LTM Mar 2026$997K +3223.3%+83.4%2.0%
APLMApollomics, Inc.FY2025$255K +254.2%+11.9%3.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K +33.3%-34.1%—
CGENCompugen Ltd.LTM Mar 2026$0 —-0.5%0.0%
Peer median (excluding ANL) $626K+104.9%+6.0%2.0%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.73M0005M
Cost of Revenue00000
Gross Profit45.73M0005M
Gross Margin100.0%———100.0%
Research & Development42.11M54.49M58.15M44.92M32.83M
Selling, General & Admin12.45M12.43M14.82M9.44M7.79M
Operating Expenses54.37M67.27M72.55M52.93M40.7M
Depreciation & Amortization1.83M2.04M2.22M1.87M1.41M
EBITDA(53.51M)(56.32M)(106.22M)(48.06M)(32.63M)
EBITDA Margin-117.0%———-652.5%
Operating Income(8.65M)(67.27M)(72.55M)(52.93M)(35.7M)
Operating Margin-18.9%———-714.0%
Interest Income32K550K62K01K
Interest Expense1.34M433K791K1.94M1.49M
Other Income / Expenses(48.03M)8.48M(36.68M)1.06M170K
Income Before Tax(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Pre-Tax Margin-124.0%———-710.6%
Income Tax Expense00000
Net Income(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Net Margin-124.0%———-710.6%
EPS (Basic)(6.66)(6.93)(15.42)(4.89)(3.33)
EPS (Diluted)(6.66)(6.93)(15.42)(4.89)(3.33)
Weighted Avg Shares8.48M8.48M6.8M10.64M10.66M
Weighted Avg Shares (Diluted)8.48M8.48M6.8M10.64M10.66M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.